United States - English - NLM (National Library of Medicine)

b. braun medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - isoleucine 0.76 g in 100 ml - parenteral nutrition with 6.9% freamine hbc® (amino acid injection) is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) nitrogen homeostasis is substantially impaired as with severe trauma or sepsis. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. see dosage and administration . central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted patients, or those requiring long-term parenteral nutrition. for moderately catabolic or deplet

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48304 - hepatitis b virus core total antibody ivd, kit, chemiluminescent immunoassay - the alinity i anti-hbc ii assay utilizes microparticles coated with recombinant hepatitis b virus core antigen (rhbcag) for the detection of anti-hbc. tthe alinity i anti-hbc ii assay is a chemiluminescent microparticle immunoassay (cmia) used for the qualitative detection of antibody to hepatitis b core antigen (anti-hbc) in human serum and plasma, including specimens collected post-mortem (non-heart beating) on the alinity i analyzer. performance has been established for the use of cadaveric blood specimens (specimens collected post-mortem, non-heartbeating) that have been collected up to 24 hours after death.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48298 - hepatitis b virus core immunoglobulin m (igm) antibody ivd, kit, chemiluminescent immunoassay - the alinity i anti-hbc igm assay utilizes acridinium-labeled recombinant hepatitis b virus core antigen (rhbcag) conjugate for the detection of anti-hbc igm. the alinity i anti-hbc igm assay is a chemiluminescent microparticle immunoassay (cmia) used for the qualitative detection of igm antibody to hepatitis b core antigen (anti-hbc igm) in human serum and plasma on the alinity i analyzer. the alinity i anti-hbc igm assay is indicated for use as an aid in the diagnosis of acute or recent hepatitis b viral infection.

Australia - English - Department of Health (Therapeutic Goods Administration)

diasorin australia pty ltd - 48304 - hepatitis b virus core total antibody ivd, kit, chemiluminescent immunoassay - the liaison? anti-hbc assay uses chemiluminescent immunoassay (clia) technology for the qualitative determination of total antibodies to hepatitis b core antigen (anti-hbc) in human serum or plasma samples. for the qualitative determination of total antibodies to hepatitis b core antigen (anti-hbc) in human serum and plasma samples, including specimens collected up to 24 hours post-mortem (non-heart beating).

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - immunology - the alinity i anti-hbc ii assay is a chemiluminescent microparticle immunoassay (cmia) used for the qualitative detection of antibody to hepatitis b core antigen (anti-hbc) in human serum and plasma, including specimens collected post-mortem (non-heartbeating) on the alinity i analyzer. the alinity i anti-hbc ii assay is intended to be used as an aid in the diagnosis of hepatitis b infection and as a screening test to prevent transmission of hepatitis b virus (hbv) to recipients of blood, blood components, cells, tissues and organs.

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - immunology - the alinity s anti-hbc assay (list no. 06p06) is a chemiluminescent microparticle immunoassay (cmia) used for the qualitative detection of antibody to hepatitis b core antigen (anti-hbc) in human serum and plasma, including specimens collected post-mortem (non-heart-beating) on the alinity s system. the alinity s anti-hbc assay is intended to be used as an aid in the diagnosis of hepatitis b infection and as a screening test to prevent transmission of hepatitis b virus (hbv) to recipients of blood, blood components, cells, tissues and organs.

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - immunology - the architect anti-hbc ii assay is a chemiluminescent microparticle immunoassay (cmia) for the qualitative detection of antibody to hepatitis b core antigen (anti-hbc) in human serum and plasma, including specimens collected post-mortem (non-heart-beating). the architect anti-hbc ii assay is intended to be used as an aid in the diagnosis of hepatitis b infection and as a screening test to prevent transmission of hepatitis b virus (hbv) to recipients of blood, blood components, cells, tissue and organs.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd diagnostic division - 48304 - hepatitis b virus core total antibody ivd, kit, chemiluminescent immunoassay - a chemiluminescent microparticle assay for the qualitative determination of anti-hbc in clinical specimens. the architect anti-hbc ii assay is a chemiluminescent microparticle immunoassay (cmia) for the qualitative detection of antibody to hepatitis b core antigen (anti-hbc) in human serum and plasma, including specimens collected post-mortem (non-heart beating) on the architect analyser. performance has been established for the use of cadaveric blood specimens (specimens collected post-mortem, non-heart beating) that have been collected up to 24 hours after death.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited - 41982 - hepatitis b virus core immunoglobulin m (igm) antibody ivd, control - precicontrol anti hbc igm is a ready for use control serum based on human serum both in the negative and positive concentration range. the controls are used for monitoring the accuracy of the elecsys anti hbc igm immunoassay. precicontrol anti hbc igm is used for quality control of the elecsys anti hbc igm immunoassay on the elecsys and cobas e immunoassay analyzers.